These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20132122)

  • 21. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence.
    Sofuoglu M; Gonzalez G; Poling J; Kosten TR
    Am J Drug Alcohol Abuse; 2003; 29(4):713-27. PubMed ID: 14713135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient satisfaction with primary care office-based buprenorphine/naloxone treatment.
    Barry DT; Moore BA; Pantalon MV; Chawarski MC; Sullivan LE; O'Connor PG; Schottenfeld RS; Fiellin DA
    J Gen Intern Med; 2007 Feb; 22(2):242-5. PubMed ID: 17356993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth.
    Subramaniam GA; Warden D; Minhajuddin A; Fishman MJ; Stitzer ML; Adinoff B; Trivedi M; Weiss R; Potter J; Poole SA; Woody GE
    J Am Acad Child Adolesc Psychiatry; 2011 Nov; 50(11):1120-8. PubMed ID: 22024000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users.
    Bazazi AR; Yokell M; Fu JJ; Rich JD; Zaller ND
    J Addict Med; 2011 Sep; 5(3):175-80. PubMed ID: 21844833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.
    Schramm ZA; Leroux BG; Radick AC; Ventura AS; Klein JW; Samet JH; Saxon AJ; Kim TW; Tsui JI
    Addict Sci Clin Pract; 2020 Jul; 15(1):30. PubMed ID: 32736660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Group medication management for buprenorphine/naloxone in opioid-dependent veterans.
    Berger R; Pulido C; Lacro J; Groban S; Robinson S
    J Addict Med; 2014; 8(6):415-20. PubMed ID: 25275875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years.
    Fiellin DA; Moore BA; Sullivan LE; Becker WC; Pantalon MV; Chawarski MC; Barry DT; O'Connor PG; Schottenfeld RS
    Am J Addict; 2008; 17(2):116-20. PubMed ID: 18393054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Effect of a Payer-Mandated Decrease in Buprenorphine Dose on Aberrant Drug Tests and Treatment Retention Among Patients with Opioid Dependence.
    Accurso AJ; Rastegar DA
    J Subst Abuse Treat; 2016 Feb; 61():74-9. PubMed ID: 26639639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).
    Potter JS; Marino EN; Hillhouse MP; Nielsen S; Wiest K; Canamar CP; Martin JA; Ang A; Baker R; Saxon AJ; Ling W
    J Stud Alcohol Drugs; 2013 Jul; 74(4):605-13. PubMed ID: 23739025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
    Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D;
    N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans.
    Amass L; Kamien JB; Mikulich SK
    Drug Alcohol Depend; 2001 Jan; 61(2):173-81. PubMed ID: 11137282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.
    Soper R; Appajosyula S; Deximo C
    Adv Ther; 2018 Apr; 35(4):457-466. PubMed ID: 29623562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inpatient initiation of buprenorphine maintenance vs. detoxification: can retention of opioid-dependent patients in outpatient counseling be improved?
    Caldiero RM; Parran TV; Adelman CL; Piche B
    Am J Addict; 2006; 15(1):1-7. PubMed ID: 16449087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
    Lofwall MR; Walsh SL; Nunes EV; Bailey GL; Sigmon SC; Kampman KM; Frost M; Tiberg F; Linden M; Sheldon B; Oosman S; Peterson S; Chen M; Kim S
    JAMA Intern Med; 2018 Jun; 178(6):764-773. PubMed ID: 29799968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients.
    Tetrault JM; Moore BA; Barry DT; O'Connor PG; Schottenfeld R; Fiellin DA; Fiellin LE
    J Subst Abuse Treat; 2012 Dec; 43(4):433-9. PubMed ID: 22938914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.
    Strain EC; Stitzer ML; Liebson IA; Bigelow GE
    J Clin Psychopharmacol; 1996 Feb; 16(1):58-67. PubMed ID: 8834420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence.
    Montoya ID; Gorelick DA; Preston KL; Schroeder JR; Umbricht A; Cheskin LJ; Lange WR; Contoreggi C; Johnson RE; Fudala PJ
    Clin Pharmacol Ther; 2004 Jan; 75(1):34-48. PubMed ID: 14749690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic.
    O'Connor PG; Oliveto AH; Shi JM; Triffleman EG; Carroll KM; Kosten TR; Rounsaville BJ; Pakes JA; Schottenfeld RS
    Am J Med; 1998 Aug; 105(2):100-5. PubMed ID: 9727815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.